ValuEngine downgraded shares of Viveve Medical (NASDAQ:VIVE) from a sell rating to a strong sell rating in a report issued on Friday.
A number of other research firms have also weighed in on VIVE. Maxim Group reiterated a buy rating and issued a $11.00 price objective on shares of Viveve Medical in a research note on Friday, August 11th. Cowen set a $11.00 price objective on shares of Viveve Medical and gave the company a buy rating in a research note on Monday, October 23rd. Finally, Mizuho began coverage on shares of Viveve Medical in a research note on Thursday, November 16th. They issued a buy rating and a $10.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The stock has an average rating of Buy and an average target price of $10.40.
Shares of Viveve Medical (NASDAQ:VIVE) opened at $5.10 on Friday. The company has a debt-to-equity ratio of 2.72, a quick ratio of 3.63 and a current ratio of 3.89. Viveve Medical has a 1-year low of $3.75 and a 1-year high of $11.16.
A number of institutional investors have recently added to or reduced their stakes in the stock. Neuberger Berman Group LLC purchased a new position in Viveve Medical in the 3rd quarter valued at approximately $419,000. Granahan Investment Management Inc. MA grew its stake in Viveve Medical by 32.6% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 102,147 shares of the company’s stock valued at $535,000 after buying an additional 25,097 shares in the last quarter. RTW Investments LP grew its stake in Viveve Medical by 18.8% in the 3rd quarter. RTW Investments LP now owns 1,473,028 shares of the company’s stock valued at $7,719,000 after buying an additional 233,585 shares in the last quarter. ING Groep NV grew its stake in Viveve Medical by 93.7% in the 3rd quarter. ING Groep NV now owns 325,000 shares of the company’s stock valued at $1,703,000 after buying an additional 157,200 shares in the last quarter. Finally, California State Teachers Retirement System purchased a new position in Viveve Medical in the 2nd quarter valued at approximately $190,000. Institutional investors and hedge funds own 67.02% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/12/04/viveve-medical-vive-downgraded-by-valuengine.html.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Viveve Medical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Viveve Medical Inc. and related companies.